Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data

Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive age-related lung disease causing relentless fibrosis of the lung parenchyma. Currently, pirfenidone and nintedanib are the two antifibrotic drugs, approved for the treatment of IPF. Both are shown to slow progression by preserv...

Full description

Bibliographic Details
Main Authors: Mohammed Ayaz Khan, Nahed Sherbini, Sami Alyami, Abdullah Al-Harbi, Majed Al-Ghamdi, Suliman Alrajhi, Rajkumar Rajendram, Hamdan Al-Jahdali
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Annals of Thoracic Medicine
Subjects:
drug side effects
idiopathic pulmonary fibrosis
mortality
nintedanib
pirfenidone
safety
tolerability
Online Access:http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2023;volume=18;issue=1;spage=45;epage=51;aulast=Khan

Internet

http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2023;volume=18;issue=1;spage=45;epage=51;aulast=Khan

Similar Items